<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ressing</surname>
    <given-names>M. E.</given-names>
   </name>
   <name>
    <surname>van Leeuwen</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Verreck</surname>
    <given-names>F. A.</given-names>
   </name>
   <name>
    <surname>Keating</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Gomez</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Franken</surname>
    <given-names>K. L.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2005</year>). 
  <article-title>Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion</article-title>. 
  <source>J. Virol.</source>
  <volume>79</volume>, 
  <fpage>841</fpage>â€“
  <lpage>852</lpage>. 
  <pub-id pub-id-type="doi">10.1128/JVI.79.2.841-852.2005</pub-id>
  <?supplied-pmid 15613312?>
  <pub-id pub-id-type="pmid">15613312</pub-id>
 </mixed-citation>
</ref>
